



STAY CURRENT with FDA-Approved Immunotherapy Treatments

Free for healthcare professionals, students, patients and patient advocates, the Society for Immunotherapy of Cancer (SITC) Advances in Cancer Immunotherapy™ (ACI) programs are CME-, CNE-, CPE- and MOC-certified and presented by local authorities in tumor immunology and cancer immunotherapy.

All healthcare professionals in the clinical setting, students, patients and patient advocates attend for FREE!
For full accreditation information or to register for Buffalo's upcoming ACI, please visit sitcancer.org/aci/buffalo

BUFFALO ACI Program Information

Saturday, Oct. 26, 2019
8:30 a.m. – 1:20 p.m. EDT

Embassy Suites Buffalo
200 Delaware Ave.
Buffalo, NY 14202

Organizers:
Christos Fountzilas, MD – *Roswell Park Comprehensive Cancer Center*
Igor Puzanov, MD, MSCI, FACP – *Roswell Park Comprehensive Cancer Center*
Cheryl Raczky, PA – *Roswell Park Comprehensive Cancer Center*

Register yourself and invite a colleague to ensure your team is up to date on the latest FDA-approved immunotherapy treatments

To register, please visit:

sitcancer.org/aci/buffalo

The 2019–2020 ACI series is jointly provided by Postgraduate Institute for Medicine and the Society for Immunotherapy of Cancer in collaboration with the American Academy of Emergency Medicine, the Association of Community Cancer Centers and the Hematology/Oncology Pharmacy Association.



Postgraduate Institute
for Medicine



Society for Immunotherapy of Cancer



AAEM
AMERICAN ACADEMY OF
EMERGENCY MEDICINE
CHAMPION OF THE EMERGENCY PHYSICIAN



Association of Community Cancer Centers



HOPA
Hematology/Oncology
Pharmacy Association

The 2019–2020 Advances in Cancer Immunotherapy™ educational series is supported, in part, by independent medical education grants from Amgen, Bristol-Myers Squibb, Celgene Corporation, Exelixis, Inc., Genentech, Incyte Corporation and Merck & Co., Inc. (as of Aug. 21, 2019).

BUFFALO ACI Program Takeaways

In addition to networking with fellow colleagues, attending ACI programs will cover how to:

- Treat patients with FDA-approved immunotherapies
- Recognize common and uncommon toxicities in immunotherapy patients and provide solutions/adjustments in treatment to address them
- Interpret new clinical data supporting the use of checkpoint inhibitors, CAR T therapies, cytokines, oncolytic viruses and vaccines
- Anticipate forthcoming immunotherapy trends/treatments/trials and how they impact your patients and practices
- Employ strategies to overcome operational and reimbursement barriers to incorporating immunotherapy into your practice

Attendees will be able to connect with regional immunotherapy experts during these interactive in-person programs, in subsequent quarterly webinars and through a dedicated SITC CONNECT online community.

AMA Credit Designation

This activity has been approved for *AMA PRA Category 1 Credit(s)™*.

Pharmacist Credit Designation

This activity is eligible for ACPE credit, see final CPE activity announcement for specific details.

Nursing Credit Designation

This activity is eligible for ANCC contact hours, see final CNE activity announcement for specific details.